Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a prospective, multicenter, phase I/II, open-label, two-stage design of PD1+ TILs infusion in metastatic or advanced TNBC. TILS001 includes 3 parts. Previous to each phase inclusion, a specific ICF must be signed by the patient. Participants potentially eligible to participate in the clinical trial will be offered to sign a ICF three times prior to TILs treatment: 1) to allow for collection of archival FFPE tissue samples for determination PD1 by mRNA (Part #1), 2) prior to a fresh metastatic biopsy for selection, isolation and partial expansion of PD1+ TILs (Part #2) and 3) prior to allow for remaining study procedures and TILs therapy (Part #3, Main Consent).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 18 lat
- •Oczekiwane przeżycie ≥6 miesięcy
- •Potwierdzony nieoperacyjny lub przerzutowy rak piersi typu potrójnie ujemnego
- •Maksymalnie 5 wcześniejszych linii chemioterapii w stadium zaawansowanym
- •Brak innego nowotworu w ciągu ostatnich 3 lat (z wyjątkami)
- •Dobry stan sprawności (ECOG 0-1)
- •Zdolność do przestrzegania wizyt i procedur badania
✗ Disqualifies
- •Ciąża lub karmienie piersią
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- November 24, 2023
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
Hospital Universitari Vall d'Hebrón
Barcelona, Spain
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital 12 de Octubre
Madrid, Spain
Clínica universidad de Navarra
Pamplona, Spain
Trial contact
Tomás Pascual
Laura Angelats
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.